title: Prezista (darunavir, TMC-114) approved; may be important treatment advance.
abstract: A major new antiretroviral has been approved, for patients resistant to more than one protease inhibitor. There is no information yet on risk/benefit compared to standard treatments for first-line use. Tibotec, which developed the drug and is now part of Johnson & Johnson, showed price restraint and avoided setting a new record high price, which other companies have done.
authors.forename: John S
authors.initials: JS
authors.lastname: James
mesh_terms: D000069454:Darunavir; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use*; D006297:Health Services Accessibility; D006801:Humans; D013449:Sulfonamides / Q000008:administration & dosage / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use*
chemical_list: D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D000069454:Darunavir